Heterozygous Men1+/T knockout mice do not develop bronchopulmonary neuroendocrine hyperplasia or neoplasia but bronchial adenocarcinoma
This study found no evidence of bronchopulmonary neuroendocrine neoplasia in Men1 knockout mice treated with lanreotide, but did observe cases of pulmonary adenocarcinoma in both treated and untreated groups.
Where it sits
this study against the rest of the lanreotide corpusSummary and findings
The study evaluated the effects of lanreotide on bronchopulmonary neuroendocrine neoplasia in a Men1 mouse model. A total of 30 mice were assessed, with 15 receiving lanreotide and 15 receiving a saline control. No bronchopulmonary neuroendocrine cell hyperplasia or neoplasia was detected in either group, though pulmonary adenocarcinoma was observed in both groups.
Abstract
<h4>Introduction: </h4> Bronchopulmonary Neuroendocrine Neoplasia (NEN) occur in 2-7% of patients with multiple endocrine neoplasia type 1 (MEN1). Precursor lesions could be recognized for MEN1 related pancreatic, duodenal, and gastric NEN. Aim of the current study of a Men1 mouse model was to define precursor lesions of bronchopulmonary NEN and potential prophylactic antitumor effects of somatostatin analogues in a transgenic Men1 mouse model. <h4>Methods: </h4>: 15 mice, germline heterozygous for Men1 (+/T), were treated with subcutaneous injections of lanreotide autogel (Somatuline Autogel®, IPSEN Pharma) and 15 mice were treated with subcutaneous injections of physiologic sodium chloride as control group. Five mice each were euthanized after 12, 15, and 18 months, respectively. The complete lungs were resected and morphologically evaluated after HE staining and immunohistochemistry for synaptophysin and chromogranin A. <h4>Results: </h4>: In the lungs of the 30 evaluated mice, treated or placebo treated, no bronchopulmonary neuroendocrine cell hyperplasia nor neuroendocrine neoplasia could be detected by histopathology. However, 2 (13%) of 15 untreated mice and one (7%) of 15 lanreotide treated mice developed pulmonary adenocarcinoma. <h4>Conclusion: </h4> Heterozygous Men1 (+/T) knockout mice do not develop bronchopulmonary NEN or precursor lesions, but pulmonary adenocarcinoma. This surprising result needs to be investigated in more detail.